Trial Profile
Evaluation of tolerability and efficacy of subcutaneous cluster-immunotherapy in patients with allergic rhinitis / rhino-conjunctivitis due to grass pollen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2016
Price :
$35
*
At a glance
- Drugs Phleum pratense cluster allergy immunotherapy ROXALL Medizin GmbH (Primary)
- Indications Allergic asthma; Allergic rhinitis; Rhinoconjunctivitis
- Focus Therapeutic Use
- Acronyms CLUSTOID
- Sponsors Roxall Medizin GmbH
- 20 Jul 2016 Status changed from recruiting to completed.
- 29 Sep 2014 New trial record